The Full Wiki

More info on Indacaterol

Indacaterol: Wikis

Advertisements
  

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Indacaterol
Systematic (IUPAC) name
(RS)-5-[2-[(5,6-Diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one
Identifiers
CAS number 312753-06-3
ATC code R03AC18
PubChem 6433117
Chemical data
Formula C24H28N2O3 
Mol. mass 392.490 g/mol
Therapeutic considerations
Pregnancy cat.  ?
Legal status

Indacaterol (INN) is an ultra long acting beta-adrenoceptor agonist[1] currently approved in Europe as Onbrez, marketed by Novartis [2][3]. It needs only be taken once a day,[4] unlike the currently available formoterol and salmeterol. Such drugs are used in the treatment of chronic obstructive pulmonary disease (COPD) and asthma. Onbrez is delivered as an aerosol formulation in the Breezhaler dry powder inhaler.

A recently published Phase III trial examined the efficacy and safety of Indacaterol in COPD patients [5]. This study, conducted in the US, New Zealand, and Belgium, compared Indacaterol dry-powder inhaler to placebo in 416 COPD patients, mostly moderate to severe (mean FEV1 of 1.5 L). Indacaterol produced statistically improved FEV1 (both trough and AUC) and decreased use of rescue medication compared to placebo, but with safety and tolerability similar to placebo.

Footnotes

  1. ^ Cazzola M, Matera MG, Lötvall J (July 2005). "Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease". Expert Opin Investig Drugs 14 (7): 775–83. doi:10.1517/13543784.14.7.775. PMID 16022567. 
  2. ^ http://www.ema.europa.eu/humandocs/Humans/EPAR/onbrez_breezhaler/onbrez_breezhaler.htm
  3. ^ (http://www.scripnews.com/researchdevelopment/Novartiss-Onbrez-Breezhaler-approved-in-EU-for-COPD-184575)
  4. ^ Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A (May 2007). "Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma". Eur. Respir. J. 29 (5): 871–8. doi:10.1183/09031936.00060006. PMID 17251236. 
  5. ^ Feldman G, Siler T, Prasad N, et al. Efficacy and safety of Indacaterol 150 mcg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010; 10:11 doi:10.1186/1471-2466-10-11.
Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message